Skip to main content
Journal of Clinical Orthopaedics and Trauma logoLink to Journal of Clinical Orthopaedics and Trauma
. 2024 Dec 13;62:102870. doi: 10.1016/j.jcot.2024.102870

Effect of platelet-rich plasma versus placebo or corticosteroid for knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials☆

Ranakishor Pelluri a,⁎, Bhima Sridevi a, Chakravarthi Guntupalli a, Prasada Chowdari Gurram a, Vanitha Rani Nagasubramanian b, Usha Sree Punnem c, Raju Kanukula d, Sivasankaran Ponnusankar e, Vishwas Hunsur Nagendra e, Uday Venkat Mateti f
PMCID: PMC11772150  PMID: 39882511

Abstract

Background

The effectiveness of intra-articular platelet-rich plasma (IA-PRP) injections for managing pain in knee osteoarthritis (KOA) remains inconsistent. Therefore, this study aimed to systematically review randomized controlled trials (RCTs) assessing the efficacy of IA-PRP.

Methods

A total of 21 studies meeting the inclusion criteria were selected from various scientific databases, all of which compared PRP to either a placebo or an active comparator, such as corticosteroids (CS), in the treatment of KOA. Weighted mean differences (WMDs) for the Visual Analogue Scale (VAS), the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and the Knee Injury and Osteoarthritis Outcome Score (KOOS), along with their 95 % confidence intervals (CIs), were calculated for each study. A subgroup analysis was conducted for the pain scores, comparing leukocyte-poor and leukocyte-rich PRP with either a placebo or CS. The evidence was synthesized using a random-effects meta-analysis.

Results

There were 2406 participants in all included studies; 1223 were in the PRP versus placebo group and 1183 were in the PRP versus corticosteroid group. The IA-PRP showed significant improvement of VAS, and WOMAC scores compared to placebo (P < 0.00.05), except KOOS score (P > 0.05). All pain scores were highly sinficant improved with IA-PRP, compared to IA-CS (P < 0.05). Additionally, the leukocyte rich PRP was efficasious than leukocyte poor PRP (P < 0.05) improving the all pain scores at the 6-month follow-up.

Conclusions

PRP treatment showed better results than placebo and corticosteroids in terms of reducing pain and improving function in KOA patients. Furthermore, lecocyte rich PRP is more effective than lecocyte poor PRP [PROSPERO, CRD42024540507].

Keywords: IA-PRP, IA-CS, Knee osteoarthritis, Meta analysis

1. Introduction

Osteoarthritis of the knee (KOA) is the second most prevalent degenerative musculoskeletal disease in adults1 and it affects worldwide 10 % of the population.2 Preventative measures and enhancing public awareness are crucial to improving the quality of life for those affected by KOA, as the disease is becoming more prevalent in most countries.3 From 1990 to 2019, the prevalence of OA increased significantly, especially in the knee, hip, and hand joints.4 Steadily KOA can be managed through adopting both pharmacological (anti-inflammatory drugs) and non-pharmacological interventions (lifestyle modification), which are minimally effective,5 despite being widely recommended.6 Several other alternatives are available to manage KOA such as IA injection of corticosteroids (CS), PRP, and hyaluronic acid (HA). Intra articular corticosteroids (IA-CS) may have side effects in addition to their limited advantages.7

Recent studies have demonstrated that biological preparations like PRP are believed to release growth agents as well as other substances, such as transforming growth factor-β (TGF-β), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF) and type I insulin-like growth factor (IGF-1) had a major role to alter joint milieu.2,8,9 Moreover, PRP had a dramatic positive response in managing KOA, its action is similar to local steroid injections10,11 and it could contribute to enhancing cartilage regenerative capacity, resulting in significant analgesic and functional benefits.12 Visco-supplementation for symptomatic KOA involves IA-HA injections. While the mechanism is unknown, it may improve synovial fluid's viscoelasticity.13 However, it has a limited role, but high molecular weight HA is effective compared to low molecular weight HA14 but it is highly expensive15 compare to PRP. IA-HA usage is debatable, and guidelines offer suggestions with caveats6 and PRP is a better management strategy than IA-HA and more effective than IA-HA in managing KOA.16, 17, 18, 19 The efficacy of PRP, leukocyte-rich, and poor PRP injections were controversial in the management of KOA. The inconsistent data prompted this review aimed at comparing the effectiveness of PRP injection Versus Placebo or IA-CS for KOA. The hypothesis was that PRP injection would treat KOA more effectively than other injectable corticosteroids.

2. Methodology

PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) rules were followed during the review procedure.20 The current review was filed under PROSPERO CRD42024540507.

2.1. Search strategy

Retrieval of literature was performed using various search engines (PubMed, Cochrane, Scopus, and Embase, as well as https://ClinicalTrials.gov), from inception to May 2024. The following search terms was used: [PRP OR platelet-rich-plasma OR LR-PRP OR Leukocyte Rich-platelet-rich-plasma OR LP-PRP OR Leukocyte Poor-platelet-rich-plasma] AND [osteoarthritis OR arthritis OR OA] AND [steroids OR corticosteroids OR Triamcinolone OR Beclomethasone] AND [knee arthritis OR arthritis OR knee osteoarthritis OR osteoarthritis]. In addition, we looked for PRP injections in combination with other steroid medications.

2.2. Study selection

This review included RCTs of IA-PRP Versus Placebo or saline and PRP versus any active comparator (corticosteroids) for individuals with KOA for a minimum of 24 weeks (regardless of the number of arms). The World Health Organization's (WHO) diagnostic criteria were used to include trials of PRP to treat osteoarthritis in the knee.

Participants, interventions, comparators, outcomes, and research design make up the PICOS approach. Research chosen for inclusion fulfilled the subsequent requirements: Those in patients with KOA pain are assessed based on a validated scoring system; Intervention: Use of IA-PRP; Comparator: IA-Placebo and or IA-CS; Outcomes: Improvement of any scores of VAS score, WOMAC score, and KOOS scores; Study design: All randomized controlled trials that were published in English.

2.3. Data extraction

The literature was meticulously extracted by four separate reviewers (RK. P., P.C.G., R.K., and VR.N) in compliance with the inclusion requirements. The first two reviewers (RK.P and P.C.G) addressed any conflicts until everyone agreed on each issue. The information retrieved from the RCTs was gathered using a standard format for data extraction and included the author's name, country, and year the study was published. Information complied with the inclusion criteria, included data, follow-up, background therapies, comparator, population mean age, mean BMI, total number of patients, gender %, total number of participants, baseline VAS,21 WOMAC,22 and KOOS,23 scores, and end of the treatment. VAS (0–10 score) was utilized to evaluate the patient's pain, and WOMAC (0–96 score) was employed to measure the pain and functional state of the patients, the highest score represents the worsening of pain and functional status. KOOS score ranges from 0 to 100 and a high score denotes less pain.

2.4. Eligibility criteria

The following three requirements have to be satisfied for the studies to be eligible for analysis: (1) RCTs comparing different IA-PRP preparations with placebo or saline or CS in KOA patients; (2) a not less than 24 weeks of follow-up; and (3) literature of English language. Literature with duplicate data was eliminated.

2.5. Risk of bias assessment

Three researchers examined the literature separately for quality and the consistency of the findings. Using the Cochrane Risk of Bias tool, biases related to selection, performance, detection, attrition, and reporting were assessed.24 After discussions, disagreements resolved themselves, and the overall risk of bias was classified as low, ambiguous, or high.25

2.6. Statistical analysis

Review Manager (formerly known as Cochrane's Review Manager) online version was applied for the analysis. The Der-Simonian and Laird random effects model was used to compute the weighted mean differences (WMDs) for the continuous outcomes. The heterogeneity between studies were expressed by the I2 statistic, with high heterogeneity defined as I2 ≥ 75 %, moderate heterogeneity as 75 % > I2 ≥ 50 %, low heterogeneity as 50 % > I2 ≥ 25 %, and no heterogeneity as I2 = 0 %.26 The efficacy of PRP's meta-analysis was performed in KOA patients (PRP Vs placebo). Furthermore, sub-group analysis (Leukocyte Poor and rich PRP Vs Placebo/CS) was used to evaluate the highly heterogeneous data (I2 ≥ 75 %).

3. Results

3.1. Literature search and study inclusion

21 RCTs that satisfied the predetermined criteria were among the 1489 entries by a title that the search turned up and was used in the analysis27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47 Fig. 1 represents the PRISMA flow chart and PRISMA check list was enclosed as Supplementary Material Table 1. These studies encompassed a total of 2406 participants, with 1786 participants in the PRP vs. Placebo group (12 RCTs)27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38 Table 1a and 620 participants in the PRP vs. CS group (9 RCTs)39, 40, 41, 42, 43, 44, 45, 46, 47 Table 1b. Patient demographic details such as age, BMI, gender percentage, baseline VAS, WOMAC, and KOOS mean scores, as well as the duration of the study, are detailed in Table 1a, Table 1b. Of 21 publications, 8 studies are used lecocyte rich PRP (LR-PRP), 7 studies used lecocyte poor PRP (LP-PRP) injections and remaing 6 studies were not noreported (Table 1a, Table 1ba and b).

Fig. 1.

Fig. 1

PRISMA flow chart outlining literature search.

Table 1a.

Baseline characteristics of studies with PRP vs Placebo.

SNo Study Subjects included Randomization/Comparator N Age (Years) BMI (Kg/m2) Gender n, (%)
VAS
Score∗
WOMAC
Score∗
KOOS Score∗ Study
Duration (months)
Male Female
1 Raeissadat SA, 2020 27 23 T PRP§ 23 57.57 ± 5.9 28.49 ± 3.24 – 23 (100) 6 ± 20.7 35 ± 16 NR 8
C Paracetamol 0.5g 23 4.7 ± 1.8 28 ± 11
2 Elnemr RA, 2019 28 30 T PRP§ 15 27.7 ± 2.9 27.2 ± 4.3 14 (93.3) 1 (6.7) 9 ± 8.5 NR 62 ± 9.8 6
C Control 15 30.1 ± 4 25.5 ± 3.3 13 (86.7) 2 (13.3) 8 ± 6.5 66.3 ± 8.7
3 Buendía LD, 2018 29 98 T PRP$ 33 56.15 ± 3.001 24.9 ± 0.32 16 (48.5) 17 (51.5) 6.15 ± 1.1 42.57 ± 7.3 NR 12
C HA 32 56.63 ± 2.9 24.9 ± 0.41 15 (46.9) 17 (53.1) 6.06 ± 0.9 42.62 ± 7.3
C Etoricoxib 60 mg OD 33 57.42 ± 3.1 25.2 ± 0.48 16 (48.5) 17 (51.5) 6.15 ± 1.2 42.66 ± 7.8
4 Elik H, 2020 30 60 T PRP§ 30 61.30 ± 7.91 30.37 ± 4.47 1 (3.3) 29 (96.7) 7.10 ± 2.52 56.40 ± 18.71 NR 6
C 0.9 % saline 30 60.19 ± 6.80 30.70 ± 3.97 3 (11.1) 24 (88.9) 7.74 ± 1.85 57.04 ± 15.12
5 Dorio M, 2021 31 62 T PRP$ 20 66.4 ± 5.6 28.3 ± 4.1 1 (5) 19 (95) 6.1 ± 1.6 52.9 ± 15.5 46.1 ± 1.21 6
C Plasma 21 66.1 ± 7.5 28 ± 3.1 2 (10) 19 (90) 5.9 ± 1.4 46.7 ± 14.3 56.1 ± 21.6
C 0.9 % saline 21 62.5 ± 8.1 27.6 ± 3.8 2 (10) 19 (90) 6.6 ± 1.4 52.3 ± 15.9 45.4 ± 15.9
6 Ghai B, 2019 32 20 T PRP$ 10 49.8 ± 9.42 NR 5 (25) 15 (75) 8.40 ± 0.883 37.5 ± 3 NR 6
C 0.9 % saline 10 7.15 ± 0.93 26.65 ± 2.9
7 Patel S, 2013 33 78 T PRP§ 27 53.11 ± 11.55 26.28 ± 3.23 11 (40.7) 16 (59.3) 4.56 ± 0.61 49.56 ± 17.83 NR 6
C PRP 25 51.64 ± 9.22 25.81 ± 3.31 5 (20) 20 (80) 4.64 ± 0.56 53.20 ± 16.18
C 0.9 % saline 23 53.65 ± 8.17 26.21 ± 2.93 6 (26.1) 17 (73.9) 4.57 ± 0.62 45.54 ± 17.29
8 Rayegani SM, 2014 34 65 T PRP§ 32 58.07 ± 8.95 28.23 ± 4.1 2 (6.5) 29 (93.5) NR 43.29 ± 15.29 NR 6
C 0.9 % saline 33 54.68 ± 10.83 27.30 ± 3.27 2 (6.5) 29 (93.5) NR 33.82 ± 22.56
9 Chu J, 2022 35 610 T PRP$ 308 53.9 ± 5.0 27.5 ± 3.2 123 (39.9) 185 (60.1) 4.83 ± 0.9 53.4 ± 11.6 NR 24
C 0.9 % saline 302 54.5 ± 5.1 27.9 ± 3.6 127 (42) 175 (58) 4.9 ± 1.1 52.6 ± 10.8
10 Tucker JD, 2021 36 17 T PRP 11 57.9 ± 1.8 30.9 ± 1.5 8 (72.7) 3 (27.3) 48.7 ± 32.5 47.7 ± 29.52 NR 12
C 0.9 % saline 6 57.2 ± 3.9 29.1 ± 2.1 2 (33.3) 4 (66.7) 37.9 ± 22.54 35.6 ± 19.84
11 Wu YT, 2018 37 20 T PRP 20 63.25 ± 6.84 24.14 ± 2.93 5 (25) 15 (75) NR 89.6 ± 36.2 NR 6
C 0.9 % saline 20 NR 72.6 ± 29.5
12 Raeissadat SA, 202138 100 T PRP$ 52 56.09 ± 6.0 27.41 ± 2.6 13 (25) 39 (75) 7.92 ± 1.0 42.73 ± 7.7 NR 12
C Ozone 30 mcg/ml 48 57.60 ± 6.1 27.01 ± 1.9 12 (25) 36 (75) 8.10 ± 1.0 42.79 ± 8.2

T: Test; C: Comparator; N: Patients/Knee Included; NR: Not reported.

∗

Baseline value.

Table 1b.

Baseline characteristics of studies with PRP vs corticosteroids.

S.No. Study Subjects included Randomization/Comparator N Age (Years) BMI (Kg/m2) Gender n, (%)
VAS
Score∗
WOMAC
Score∗
KOOS
Score∗
Study
Duration (months)
Male Female
1 Huang Y, 2019 39 120 T PRP$ 40 54.5 ± 1.2 25.23 ± 4.15 25 (62.5) 15 (37.5) 4.57 ± 0.61 48.19 ± 4.96 NR 12
C HA 40 54.8 ± 1.1 24.51 ± 3.09 19 (47.5) 21 (52.5) 4.54 ± 0.59 47.23 ± 5.37
C CS 40 54.3 ± 1.4 24.56 ± 3.62 21 (52.5) 19 (47.5) 4.64 ± 0.54 46.58 ± 5.74
2 Güvendi EU, 2018 40 50 T PRP§ 14 62.3 ± 1.6 31.4 ± 0.7 1 (7.1) 13 (92.9) 6.9 ± 0.8 58.1 ± 3.3 NR 6
C PRP-3 19 60.4 ± 1.7 31.0 ± 1.0 1 (5.3) 18 (94.7) 8.0 ± 0.5 62.9 ± 4.2
C CS-Beclomethasone 17 62.8 ± 1.7 31.1 ± 1.0 2 (11.8) 15 (88.2) 8.4 ± 0.3 59.7 ± 3.2
3 Forogh B, 2016 41 48 T PRP 24 59.13 ± 7.03 28.9 2.8 7 (29.2) 17 (70.8) 8.13 ± 1.34 NR 45.8 ± 13.5 6
C CS-MPA 40 mg 24 61.13 ± 6.7 29.2 3.4 9 (37.5) 15 (62.5) 7.78 ± 1.38 52.3 ± 11.8
4 Freire MR, 2020 42 50 T PRP 25 64.15 ± 8.02 NR 8 (16) 42 (84) 42.44 73.9 42.4 6
C CS-Triamcinolone 40 mg 25 60.21 ± 5.92 49.96 63.93 49.96
5 Joshi JN, 2017 43 65 T PRP$ 35 65.56 ± 8.6 31.20 ± 4.36 12 (34.3) 23 (65.7) 7.5 ± 1.01 NR 35.11 ± 17.94 6
C CS-Beclomethasone 30 68 ± 7.17 30.98 ± 4.16 6 (20) 24 (80) 7.5 ± 0.93 38.80 ± 18.99
6 Nabi BN, 2018 44 67 T PRP 34 59.9 ± 7.7 28.4 ± 2.7 5 (14.7) 28 (85.3) 7.36 ± 0.9 NR 35.26 ± 8.9 6
C CS-Triamcinolone 40 mg 33 58.5 ± 8.7 27.7 ± 3.2 7 (18.2) 27 (81.8) 7.12 ± 1.29 38.97 ± 12.89
7 Elksniņs FA, 2020 45 40 T PRP 20 66.4 ± 8.4 28.6 ± 5.0 17 (85) 3 (15) 6.1 ± 1.2 NR NR 12
C CS 20 70.2 ± 9.2 30.5 ± 5.8 15 (75) 5 (25) 6.0 ± 1.4
8 Turgut MC, 2022 46 98 T PRP§ 49 68.12 ± 7.34 32.04 ± 1.59 15 (30.6) 22 (69.4) 7.47 ± 1.12 NR 7.47 ± 1.12 6
C PRP/CS-1 49 67.78 ± 7.62 31.43 ± 1.29 34 (44.9) 27 (55.1) 8.59 ± 1.1 24.18 ± 5.89
9 Kumar A, 2021 47 82 T PRP§ 42 63.8 ± 9.4 NR 12 (28.5) 30 (71.5) 7 ± 2.5 78.5 ± 10.5 NR 6
C CS 40 64.7 ± 9.1 15 (37.5) 25 (62.5) 7 ± 2 52.5 ± 10.5

T: Test; C: Comparator; N: Patients/Knee Included; NR: Not reported; §: Leukocyte Rich PRP; $: Leukocyte Poor PRP.

∗

: Baseline value.

3.2. Improvement of VAS score

The VAS score was assessed for 16 trials in total, 8 of which compared PRP Vs placebo,27, 28, 29, 30, 31, 32, 33,35 and 8 of which compared PRP Vs CS.39, 40, 41,43, 44, 45, 46, 47 A significant reduction of VAS score was noticed in PRP treated group. significant Compared to placebo PRP treated group showed significant reduction of VAS score [WMD -1.67; 95 % CI [−2.85 to −0.48]; P = 0.006; I2 = 98 %]. The VAS score reduction was much significant when caomared to CS [WMD -1.99; 95 % CI [−3.15 to −0.82]; P = 0.0008; I2 = 96 %] (Fig. 2, Fig. 3). Furthermore, subgroup anlysis was done between LR, LP- PRP Vs plaebo/CS. Reduction of VSA score was significant in LR-PRP [WMD -2.46; 95 % CI [−3.77 to −1.15]; P = 0.0002; I2 = 97 %] (Supplementary Material Fig. 1)

Fig. 2.

Fig. 2

Effect of IA-PRP Vs Placebo in reduction of VAS Score in KOA.

Fig. 3.

Fig. 3

Effect of IA-PRP Vs CS in reduction of VAS Score in KOA.

3.3. Improvement of WOMAC score

A total of fourteen studies were included, of which 10 studies are PRP Vs Placebo27,29, 30, 31, 32, 33, 34, 35, 37,38 and 4 are PRP Vs CS.39,40,42,47 The improvement of WOMAC score in PRP treated group was statistically significant [WMD of −15.18, 95 % CI [−23.22 to −7.14]; P = 0.0002] compared to placebo Fig. 4. With respect to CS treated group, the results were favouring PRP [WMD of −11.94, 95 % CI [−22.20 to −1.68]; P = 0.02] Fig. 5. The subgroup anlysis was performed among lecocyte poor and rich PRP Vs plaebo/CS. The reduction of WOMAC score was highly significant in LR-PRP [WMD -10.56; 95 % CI [−16.27 to −4.85]; P = 0.0003; I2 = 83 %], compared to LP-PRP [WMD -16.51; 95 % CI [−26.78 to −6.24]; P = 0.002; I2 = 98 %] (Supplementary Material Fig. 2),

Fig. 4.

Fig. 4

Effect of IA-PRP Vs Placebo in reduction of WOMAC Score in KOA.

Fig. 5.

Fig. 5

Effect of IA-PRP Vs CS in reduction of WOMAC Score in KOA.

3.4. Improvement of KOOS score

A total of seven studies assessed the KOOS score, of which 2 are PRP vs. placebo28,31, and 9 are PRP Vs CS.41,43,44,46 The improvement of score is not significant compared to placebo (P = 0.77) Fig. 6. The increase of KOOS score was statistically signigicant compared to CS [WMD 21.85; 95 % CI [14.54 to 2.15]; P = 0.00001; I2 = 86 %] Fig. 7. The subgroup anlysis was performed among lecocyte poor and rich PRP Vs plaebo/CS. The increase of KOOS score was significant in LR-PRP [WMD 18.49; 95 % CI [0.99 to 35.98]; P = 0.04; I2 = 97 %], compared to LP-PRP (P = 0.92) (Supplementary Material Fig. 3)

Fig. 6.

Fig. 6

Effect of IA-PRP Vs Placebo in increase of KOOS Score in KOA.

Fig. 7.

Fig. 7

Effect of IA-PRP Vs CS in increase of KOOS Score in KOA.

3.5. Quality assessment of studies

The Cochrane Risk of Bias Assessment Tool (RevMan 5.4) was applied to assess each of the 21 included RCTs' risk of bias (RoB-1). Considerable risk of performance bias resulted from improper participant and staff blinding in seven of these research. In three more investigations, there was a substantial possibility of detecting bias as a result of inadequate blinding during the evaluation of result indicators. Allocation concealment was found to be lacking in 2 studies, resulting in the two investigations finding a considerable probability of selection and attrition bias. Overall, the included RCTs revealed a low risk of bias Publication bias was analyzed for the studies included 10 or more. The visual inspection of funnel plot indicates there was no publication bias for the included studies (Supplementary Material Figs. 4–6).

4. Discussion

The present review analyzed the effectiveness of PRP treatment in KOA and aimed at providing concise evidence with RCTs of a minimum follow-up of 24 weeks. The improvement of VAS, WOMAC, and KOOS scores following this review indicates showing PRP works better for treating KOA than IA-CS or a placebo. The higher scores of WOMAC and VAS indicated worsening pain, whereas a higher KOOS score indicated lesser pain. The present systematic review included 21 RCTs of which, 12 studies assessed intraarticular PRP against placebo and 9 studies assessed PRP against CS.

At the end of two months, three months, and six months, between the PRP and CS groups, the mean WOMAC and VAS ratings significantly decreased. The PRP treated group showed a significantly higher weighted mean difference, particularly after six and twelve months from baseline. Similarly, from baseline to six months, there was a significant weighted mean difference in the mean KOOS scores between the PRP treated groups and the CS treated groups, according to the four investigations. Within three months of treatment, studies using both PRP and CS injections in KOA patients showed decreased pain and increased physical function. Nevertheless, compared to CS, PRP was found to be more successful in providing long-term pain alleviation, particularly one that lasted for up to 12 months.45 Making PRP a valid treatment option in early-stage KOA,39 preferably more successful in patients with lesser degrees of cartilage degradation who are comparatively younger.47 For pain reduction, increasing daily activities, and improving quality of life in individuals with late-stage knee OA, a single PRP injection was found to be more effective than one dosage of CS; however, in patients older than 67, the results were similar to those of a single CS dose.43 According to the Uslu et al., 2018 study, PRP injections are safe and effective, with no side effects and no discernible difference between single and repeated injections.40 Overall, the investigations on PRP Vs CS reported that PRP injections were more effective even after 3 months post-intervention, lessening the need for re-administration unlike once in three months CS injections.

Reports on PRP's effectiveness have been inconsistent due to the variability in the evidence in specific indications other than KOA, such as tendinopathy of patellar and achilles, tendon related disorders.48, 49, 50, 51 When compared to placebo, ozone, or hyaluronic acid, PRP has been shown in several RCTs to be helpful for KOA. This suggests that intraarticular PRP infiltrations may provide measurable advantages for reducing pain and enhancing functionality for a maximum of one year.52, 53, 54, 55, 56 Studies have also shown that the effectiveness of PRP injections declined 24 months after a year of clinical improvements. This decline was notably seen in younger patients with mild to moderate cartilage degradation. A single PRP injection had resulted in a significant pain decrease after 3 months lasting up to 12 months, indicating the need for number of PRP injections for a sustained beneficial effect.51,57 However, WOMAC ratings did not significantly differ six weeks between single and double PRP injections, 3 months, or 6 months in early KOA, according to Patel S et al.33 Studies on PRP vs placebo included in this review also have reported the benefit of PRP over saline or placebo in KOA for 12 months with a single intervention of PRP. In Chu J. et al.'s long-term 60-month follow-up experiment, PRP vs sham saline. Although the PRP group's gain in clinical scores was still statistically and clinically better to saline or placebo, the data showed that it was only stable for up to 24 months before dropping at 60 months.35 After a year of treatment, MRI results further supported a study by Raeissadat et al. that found a substantial comparison between the PRP group to the saline-treated group, there was an improvement in the amount of patellofemoral cartilage and synovitis.27 In addition to a notable decline in the WOMAC and VAC ratings and an improvement in the three-month KOOS scores which was more pronounced at 6 months, Elnemr et al., have also reported a significant decrease in the percentage of cartilage degeneration following meniscal repair.28

Treating OA nonoperatively has become imperative in recent decades and investigations have indicated IA-PRP injections have greater advantages than HA or CS injections in terms of clinical results while treating symptomatic KOA at the time of follow-up. The well-documented anti-inflammatory and analgesic effects of PRP have led to an upsurge in its usage in the fields of orthopedics, dentistry, and plastic surgery, especially for tissue regeneration and wound healing. PRP has been discovered to repair avascular injured tissues with limited potential for self-healing, such as ligaments, cartilage, and tendons, by enhancing motor function and promoting the synthesis of collagen, angiogenesis, and cell proliferation.58, 59, 60 While the effectiveness of platelet-derived growth factor (PDGF), transforming growth factor (TGF)-β, vascular endothelial growth factor (VEGF), epidermal growth factor, hepatocyte growth factor, fibroblast growth factor, and insulin-like growth factor are among the growth factors that may be present in the platelets known as α particles, according to studies.61,62 Secondary to an injection of PRP in KOA, activation of exogenous factors occurs within 10 min, followed by platelets aggregation and coagulation in the joint cavity and secretion of large amounts of cytokines and growth factors by 95 % of α particles within an hour.63 Following platelet activation, the release of these bioactive factors, especially TGF-β and PDGF into the bloodstream significantly results in tissue regeneration and repair.64 By interfering with chondrocytes' regular metabolic activity and preventing normal chondrocyte development, TGF-β works to suppress Interleukin (IL)-1β, which is responsible for chondrocyte death.65 Furthermore, activin receptor-like kinases-5 (ALK-5), which control cartilage terminal differentiation, are activated by TGF-β. As a result, bone marrow mesenchymal stem cells differentiate into chondrocytes, which encourages the growth and differentiation of chondrocytes while reducing the production of inflammatory markers. PDGF increases the production of collagen and encourages osteoblast and fibroblast proliferation and chemotaxis.66 The plasma proteins in PRP further stimulate fibrinogen to create fibrin scaffolds and promote chondrocyte development and differentiation, which will help cartilage damage recover.67

The enhanced efficacy of PRP injections over CS or HA injections could also be attributed to the effects of PRP infiltrations on the joints other than its anti-inflammatory function.45 The tissue maturation induced by PRP is secondary to the proliferation of cells that are capable of producing superficial zone proteins which can act as lubricants and the enhanced secretion of HA by PRP acting as a lubricant can cause a reduction of friction and stress in OA joints.68 Studies have also indicated that variations in the PRP preparations utilized, such as the platelet volume and concentration, its purity, and different preparation techniques and concentrations, leading to different products, may account for the varied effects in transforming the degenerative articular environment into a regenerative environment. Furthermore, variations in the quantity and duration of injections may impact the efficacy of PRP injections.69,70 Furthermore, no substantial adverse effects have been linked to PRP injections in any of the studies included in the meta-analysis.71, 72, 73, 74

In contrast to effect of LP & LR-PRP injections in controlling pain and function was assessed in present review. Both LR-PRP and LP-PRP was effective in reducing WOMAC score, however the subgroup difference was not significant. LP-PRP was not effective in improving VAS and KOOS score. Where as LR-PRP was effective in reducing all pain and function scales. Di Martino A et al., conducted double blinded RCT in 192 patients with KOA, they found no significant differences in clinical outcomes between LR-PRP and LP-PRP over 12 months.75 A recent systematic review assessed the pain & function with LR & LP-PRP. Both have shoewed significant improvement at 12 months of followup.76 Limited evidence exists in KOA regarding the optimal PRP formulations. The role of leukocytes in PRP, a key factor in distinguishing formulations, remains highly debated. Some in vitro and preclinical studies suggest that LR-PRP increases catabolic cascades and inflammatory cytokines like IL-1 and TNF-α, leading to concerns about its use in conditions like KOA. Consequently, leukocyte-poor PRP (LP-PRP) is often recommended for managing inflammation.77,78 Studies also report that neutrophils stimulate platelets to release VEGF and increase anti-inflammatory cytokines like IL-4 & IL-10.79,80 Both LR & LP-PRP have distinct advantages and limitations, requiring clinicians to tailor treatment based on patient needs, goals, and existing evidence. Factors like age, health status, gender, and ethnicity also influence PRP effectiveness, beyond leukocyte levels. In the review of Abbas et al., reported leukocyte concentration of PRP does not play a significant role in patient-reported outcome measures for KOA.81 Hence, it is essential to do further research, especially randomised trials, to identify the best PRP formulations for various ailments. Maximising PRP's therapeutic potential by the integration of clinical evidence and patient-specific characteristics can support its role in personalised regenerative medicine and facilitate more efficacious treatment approaches.

5. Conclusion

The efficacy of IA-PRP in reducing pain and enhancing functional activity in KOA patients is supported by this meta-analysis with a higher level of safety when compared to IA-CS, enabling it a suitable candidate for clinical application in KOA. Moreover the LR-PRP was more effective than LP-PRP in improvement of pain scores of VAS, WOMAC and KOOS. However, the effectiveness of PRP injections was sustained for up to 12 months followed by which there was deterioration. This signifies a need for more number long term studies in larger populations comparing the efficiency of PRP injections in KOA.

Author’s contribution

RKP, C.G and P.C.G.: Conceptualization, Methodology, Software B.S.,VR.N and U.P: Data curation, Writing – original draft. R.K., S.P.: Visualization, Investigation. VH.N., C.G and UV.M: Supervision: RKP., VR.N and C.G: Software, Validation.: RKP and UV.M: Writing- Reviewing and Editing.

Ethical approval

The present systematic review was registered in PROSPERO, with identification No. CRD42024540507.

Consent to participate

Not applicable.

Consent for publication

All the listed authors have thoroughly reviewed the manuscript and have approved it.

Authors contribution

All authors are equally contributed until completion of work.

Funding

Self-funded

Declaration of competing interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Ranakishor Pelluri reports statistical analysis was provided by Koneru Lakshmaiah Education Foundation. Ranakishor Pelluri reports was provided by Koneru Lakshmaiah Education Foundation. Ranakishor Pelluri reports a relationship with Koneru Lakshmaiah Education Foundation that includes: non-financial support. Koneru Lakshmaiah Education Foundation has patent pending to na. na If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

Mutual thanks to all authors.

Footnotes

☆

We confirm that the content of the manuscript has not been published or submitted for publication elsewhere.

Appendix A

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jcot.2024.102870.

Appendix A. Supplementary data

The following are the Supplementary data to this article.

Multimedia component 1
mmc1.docx (356.3KB, docx)
Multimedia component 2
mmc2.docx (45.5KB, docx)

References

  • 1.Deshpande B.R., Katz J.N., Solomon D.H., et al. Number of persons with symptomatic knee osteoarthritis in the US: impact of race and ethnicity, age, sex, and obesity. Arthritis Care Res. 2016 Dec;68(12):1743–1750. doi: 10.1002/acr.22897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Demange M.K., Sisto M., Rodeo S. Future trends for unicompartmental arthritis of the knee: injectables & stem cells. Clin Sports Med. 2014;33(1):161–174. doi: 10.1016/j.csm.2013.06.006. [DOI] [PubMed] [Google Scholar]
  • 3.Yang G., Wang J., Liu Y., et al. Burden of knee osteoarthritis in 204 countries and territories, 1990–2019: results from the Global Burden of Disease Study 2019. Arthritis Care Res. 2023 Dec;75(12):2489–2500. doi: 10.1002/acr.25158. [DOI] [PubMed] [Google Scholar]
  • 4.Long H., Liu Q., Yin H., et al. Prevalence trends of site‐specific osteoarthritis from 1990 to 2019: findings from the global burden of disease study 2019. Arthritis Rheumatol. 2022 Jul;74(7):1172–1183. doi: 10.1002/art.42089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Fransen M., McConnell S., Harmer A.R., Van der Esch M., Simic M., Bennell K.L. Exercise for osteoarthritis of the knee: a Cochrane systematic review. Br J Sports Med. 2015 Dec 1;49(24):1554–1557. doi: 10.1136/bjsports-2015-095424. [DOI] [PubMed] [Google Scholar]
  • 6.Bannuru R.R., Osani M.C., Vaysbrot E.E., et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019 Nov 1;27(11):1578–1589. doi: 10.1016/j.joca.2019.06.011. [DOI] [PubMed] [Google Scholar]
  • 7.Nelson A.E., Allen K.D., Golightly Y.M., Goode A.P., Jordan J.M. vol. 43. WB Saunders; 2014 Jun 1. A systematic review of recommendations and guidelines for the management of osteoarthritis: the chronic osteoarthritis management initiative of the US bone and joint initiative; pp. 701–712. (InSeminars in Arthritis and Rheumatism). 6. [DOI] [PubMed] [Google Scholar]
  • 8.Boswell S.G., Cole B.J., Sundman E.A., Karas V., Fortier L.A. Platelet-rich plasma: a milieu of bioactive factors. Arthrosc J Arthrosc Relat Surg. 2012 Mar 1;28(3):429–439. doi: 10.1016/j.arthro.2011.10.018. [DOI] [PubMed] [Google Scholar]
  • 9.Zhu Y., Yuan M., Meng H.Y., et al. Basic science and clinical application of platelet-rich plasma for cartilage defects and osteoarthritis: a review. Osteoarthritis Cartilage. 2013 Nov 1;21(11):1627–1637. doi: 10.1016/j.joca.2013.07.017. [DOI] [PubMed] [Google Scholar]
  • 10.Kon E., Buda R., Filardo G., et al. Platelet-rich plasma: intra-articular knee injections produced favorable results on degenerative cartilage lesions. Knee Surg Sports Traumatol Arthrosc. 2010 Apr;18:472–479. doi: 10.1007/s00167-009-0940-8. [DOI] [PubMed] [Google Scholar]
  • 11.Sampson S., Reed M., Silvers H., Meng M., Mandelbaum B. Injection of platelet-rich plasma in patients with primary and secondary knee osteoarthritis: a pilot study. Am J Phys Med Rehabil. 2010 Dec 1;89(12):961–969. doi: 10.1097/PHM.0b013e3181fc7edf. [DOI] [PubMed] [Google Scholar]
  • 12.Küffer J., Ziltener J.L. PRP and knee osteoarthritis. Rev Med Suisse. 2022 Jan 1;18(766):127–130. doi: 10.53738/REVMED.2022.18.766.127. [DOI] [PubMed] [Google Scholar]
  • 13.Wen D.Y. Intra-articular hyaluronic acid injections for knee osteoarthritis. Am Fam Physician. 2000 Aug 1;62(3):565–570. [PubMed] [Google Scholar]
  • 14.Ferkel E., Manjoo A., Martins D., Bhandari M., Sethi P., Nicholls M. Intra-articular hyaluronic acid treatments for knee osteoarthritis: a systematic review of product properties. Cartilage. 2023 Dec;14(4):424–432. doi: 10.1177/19476035231154530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Landi S., Russo S., Landa P. Knee OA management: a cost-effectiveness analysis of platelet-rich-plasma versus hyaluronic acid for the intra-articular treatment of knee OA in France. Int J Clin Rheumatol. 2018;13(5):307–318. [Google Scholar]
  • 16.Holguin E. Platelet-rich plasma injection is more effective than hyaluronic acid in the treatment of knee osteoarthritis. Orthopaedic Journal of Sports Medicine. 2014 Dec 29;2(12_suppl 4) [Google Scholar]
  • 17.Say F., Güler D., Yener K., Bülbül M., Malkoç M. Platelet-rich plasma injection is more effective than hyaluronic acid in the treatment of knee osteoarthritis. Acta Chir Orthop Traumatol Cech. 2013;80(4):278–283. [PubMed] [Google Scholar]
  • 18.Li S., Xing F., Yan T., Zhang S., Chen F. Multiple injections of platelet-rich plasma versus hyaluronic acid for knee osteoarthritis: a systematic review and meta-analysis of current evidence in randomized controlled trials. J Personalized Med. 2023 Feb 27;13(3):429. doi: 10.3390/jpm13030429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Gong H., Li K., Xie R., et al. Clinical therapy of platelet-rich plasma vs hyaluronic acid injections in patients with knee osteoarthritis: a systematic review and meta-analysis of randomized double-blind controlled trials. Medicine. 2021 Mar 26;100(12) doi: 10.1097/MD.0000000000025168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Hutton B., Salanti G., Caldwell D.M., et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015 Jun 2;162(11):777–784. doi: 10.7326/M14-2385. [DOI] [PubMed] [Google Scholar]
  • 21.Jensen M.P., Karoly P., Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain. 1986;27:117–126. doi: 10.1016/0304-3959(86)90228-9. [DOI] [PubMed] [Google Scholar]
  • 22.Bellamy N., Buchanan W.W., Goldsmith C.H., Campbell J., Stitt L.W. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(12):1833–1840. [PubMed] [Google Scholar]
  • 23.Roos E.M., Roos H.P., Lohmander L.S., Ekdahl C., Beynnon B.D. Knee injury and osteoarthritis outcome score (KOOS)- development of a self-administered outcome measure. J Orthop Sports Phys Ther. 1998;28(2):88–96J. doi: 10.2519/jospt.1998.28.2.88. [DOI] [PubMed] [Google Scholar]
  • 24.Sterne J.A., Savović J., Page M.J., et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Br Med J. 2019 Aug;28 doi: 10.1136/bmj.l4898. 366. [DOI] [PubMed] [Google Scholar]
  • 25.Higgins J.P.T., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560. doi: 10.1136/bmj.327.7414.557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Sweeting M.J., Sutton A.C., Lambert P. What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data. Stat Med. 2004 May 15;23(9):1351–1375. doi: 10.1002/sim.1761. [DOI] [PubMed] [Google Scholar]
  • 27.Raeissadat S.A., Ghorbani E., Sanei Taheri M., et al. MRI changes after platelet rich plasma injection in knee osteoarthritis (randomized clinical trial) J Pain Res. 2020 Jan;10:65–73. doi: 10.2147/JPR.S204788. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Elnemr R.A., Abdelnaby H.M., Elshafei M.M. Does intra-articular platelet rich plasma injection improve meniscal repair outcomes? Asian J Sports Med. 2019 Sep 30;10(3) [Google Scholar]
  • 29.Buendía-López D., Medina-Quirós M., Fernández-Villacañas Marín M.Á. Clinical and radiographic comparison of a single LP-PRP injection, a single hyaluronic acid injection and daily NSAID administration with a 52-week follow-up: a randomized controlled trial. J Orthop Traumatol. 2018 Dec;19:1–9. doi: 10.1186/s10195-018-0501-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Elik H., Doğu B., Yılmaz F., Begoğlu F.A., Kuran B. The efficiency of platelet-rich plasma treatment in patients with knee osteoarthritis. J Back Musculoskelet Rehabil. 2020 Jan 1;33(1):127–138. doi: 10.3233/BMR-181374. [DOI] [PubMed] [Google Scholar]
  • 31.Dório M., Pereira R.M., Luz A.G., Deveza L.A., de Oliveira R.M., Fuller R. Efficacy of platelet-rich plasma and plasma for symptomatic treatment of knee osteoarthritis: a double-blinded placebo-controlled randomized clinical trial. BMC Muscoskel Disord. 2021 Dec;22:1–2. doi: 10.1186/s12891-021-04706-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Ghai B., Gupta V., Jain A., Goel N., Chouhan D., Batra Y.K. Effectiveness of platelet rich plasma in pain management of osteoarthritis knee: double blind, randomized comparative study. Rev Bras Anestesiol. 2019 Dec 20;69:439–447. doi: 10.1016/j.bjane.2019.06.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Patel S., Dhillon M.S., Aggarwal S., Marwaha N., Jain A. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial. Am J Sports Med. 2013 Feb;41(2):356–364. doi: 10.1177/0363546512471299. [DOI] [PubMed] [Google Scholar]
  • 34.Rayegani S.M., Raeissadat S.A., Taheri M.S., et al. Does intra articular platelet rich plasma injection improve function, pain and quality of life in patients with osteoarthritis of the knee? A randomized clinical trial. Orthop Rev. 2014 Aug 8;6(3) doi: 10.4081/or.2014.5405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Chu J., Duan W., Yu Z., et al. Intra‐articular injections of platelet‐rich plasma decrease pain and improve functional outcomes than sham saline in patients with knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2022 Dec;30(12):4063–4071. doi: 10.1007/s00167-022-06887-7. [DOI] [PubMed] [Google Scholar]
  • 36.Tucker J.D., Goetz L.L., Duncan M.B., et al. Randomized, placebo‐controlled analysis of the knee synovial environment following platelet‐rich plasma treatment for knee osteoarthritis. PM&R. 2021 Jul;13(7):707–719. doi: 10.1002/pmrj.12561. [DOI] [PubMed] [Google Scholar]
  • 37.Wu Y.T., Hsu K.C., Li T.Y., Chang C.K., Chen L.C. Effects of platelet-rich plasma on pain and muscle strength in patients with knee osteoarthritis. Am J Phys Med Rehab. 2018 Apr 1;97(4):248–254. doi: 10.1097/PHM.0000000000000874. [DOI] [PubMed] [Google Scholar]
  • 38.Raeissadat S.A., Ghazi Hosseini P., Bahrami M.H., et al. The comparison effects of intra-articular injection of Platelet Rich Plasma (PRP), Plasma Rich in Growth Factor (PRGF), Hyaluronic Acid (HA), and ozone in knee osteoarthritis; a one year randomized clinical trial. BMC Muscoskel Disord. 2021 Dec;22:1–4. doi: 10.1186/s12891-021-04017-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Huang Y., Liu X., Xu X., Liu J. Intra-articular injections of platelet-rich plasma, hyaluronic acid or corticosteroids for knee osteoarthritis: a prospective randomized controlled study. Orthopä. 2019 Mar 1;48(3):239–247. doi: 10.1007/s00132-018-03659-5. [DOI] [PubMed] [Google Scholar]
  • 40.Güvendi E.U., Aşkin A., Güvendi G., Koçyiğit H. Comparison of efficiency between corticosteroid and platelet rich plasma injection therapies in patients with knee osteoarthritis. Archives of rheumatology. 2018 Sep;33(3):273. doi: 10.5606/ArchRheumatol.2018.6608. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Forogh B., Mianehsaz E., Shoaee S., Ahadi T., Raissi G.R., Sajadi S. Effect of single injection of platelet-rich plasma in comparison with corticosteroid on knee osteoarthritis: a double-blind randomized clinical trial. J Sports Med Phys Fit. 2016 Jul 1;56(7-8):901–908. [PubMed] [Google Scholar]
  • 42.Freire M.R., da Silva P.M., Azevedo A.R., Silva D.S., da Silva R.B., Cardoso J.C. Comparative effect between infiltration of platelet-rich plasma and the use of corticosteroids in the treatment of knee osteoarthritis: a prospective and randomized clinical trial. Revista Brasileira de Ortopedia. 2020 Dec 2;55:551–556. doi: 10.1016/j.rbo.2018.01.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Joshi Jubert N., Rodríguez L., Reverté-Vinaixa M.M., Navarro A. Platelet-rich plasma injections for advanced knee osteoarthritis: a prospective, randomized, double-blinded clinical trial. Orthopaedic journal of sports medicine. 2017 Feb 13;5(2) doi: 10.1177/2325967116689386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Nabi B.N., Sedighinejad A., Mardani-Kivi M., Haghighi M., Roushan Z.A., Biazar G. Comparing the effectiveness of intra-articular platelet-rich plasma and corticosteroid injection under ultrasound guidance on pain control of knee osteoarthritis. Iran Red Crescent Med J. 2018 Mar 1;20(3) [Google Scholar]
  • 45.Elksniņš-Finogejevs A., Vidal L., Peredistijs A. Intra-articular platelet-rich plasma vs corticosteroids in the treatment of moderate knee osteoarthritis: a single-center prospective randomized controlled study with a 1-year follow up. J Orthop Surg Res. 2020 Dec;15 doi: 10.1186/s13018-020-01753-z. 1-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Turgut M.C., Ayas M.S., Okay E., Yıldırım Ö.S. Multiple injections of PRP/steroid combination result in better clinical outcames in advanced osteoarthritis: a prospective randomized study. New Trends in Medicine Sciences. 2022 Jan 1;3(1):36–42. [Google Scholar]
  • 47.Kumar A., Kumar N., Kumar A. A comparative study betwee n role of platelet rich plasma (PRP) and corticosteroid injectio n in the treatment of osteoarthritis knee. Int J Orthop Sci. 2021;7:263–267. [Google Scholar]
  • 48.Scott A., LaPrade R.F., Harmon K.G., et al. Platelet-rich plasma for patellar tendinopathy: a randomized controlled trial of leukocyte-rich PRP or leukocyte-poor PRP versus saline. Am J Sports Med. 2019 Jun;47(7):1654–1661. doi: 10.1177/0363546519837954. [DOI] [PubMed] [Google Scholar]
  • 49.de Jonge S., de Vos R.J., Weir A., et al. One-year follow-up of platelet-rich plasma treatment in chronic Achilles tendinopathy: a double-blind randomized placebo-controlled trial. Am J Sports Med. 2011 Aug;39(8):1623–1630. doi: 10.1177/0363546511404877. [DOI] [PubMed] [Google Scholar]
  • 50.Le A.D., Enweze L., DeBaun M.R., Dragoo J.L. Current clinical recommendations for use of platelet-rich plasma. Current reviews in musculoskeletal medicine. 2018 Dec;11:624–634. doi: 10.1007/s12178-018-9527-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Filardo G., Kon E., Buda R., et al. Platelet-rich plasma intra-articular knee injections for the treatment of degenerative cartilage lesions and osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2011 Apr;19:528–535. doi: 10.1007/s00167-010-1238-6. [DOI] [PubMed] [Google Scholar]
  • 52.Shen L., Yuan T., Chen S., Xie X., Zhang C. The temporal effect of platelet-rich plasma on pain and physical function in the treatment of knee osteoarthritis: systematic review and meta-analysis of randomized controlled trials. J Orthop Surg Res. 2017 Dec;12:1–2. doi: 10.1186/s13018-017-0521-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Ye Y., Zhou X., Mao S., Zhang J., Lin B. Platelet rich plasma versus hyaluronic acid in patients with hip osteoarthritis: a meta-analysis of randomized controlled trials. Int J Surg. 2018 May 1;53:279–287. doi: 10.1016/j.ijsu.2018.03.078. [DOI] [PubMed] [Google Scholar]
  • 54.Meheux C.J., McCulloch P.C., Lintner D.M., Varner K.E., Harris J.D. Efficacy of intra-articular platelet-rich plasma injections in knee osteoarthritis: a systematic review. Arthrosc J Arthrosc Relat Surg. 2016 Mar 1;32(3):495–505. doi: 10.1016/j.arthro.2015.08.005. [DOI] [PubMed] [Google Scholar]
  • 55.Dai W.L., Zhou A.G., Zhang H., Zhang J. Efficacy of platelet-rich plasma in the treatment of knee osteoarthritis: a meta-analysis of randomized controlled trials. Arthrosc J Arthrosc Relat Surg. 2017 Mar 1;33(3):659–670. doi: 10.1016/j.arthro.2016.09.024. [DOI] [PubMed] [Google Scholar]
  • 56.Laudy A.B., Bakker E.W., Rekers M., Moen M.H. Efficacy of platelet-rich plasma injections in osteoarthritis of the knee: a systematic review and meta-analysis. Br J Sports Med. 2015 May 1;49(10):657–672. doi: 10.1136/bjsports-2014-094036. [DOI] [PubMed] [Google Scholar]
  • 57.Fukawa T., Yamaguchi S., Akatsu Y., Yamamoto Y., Akagi R., Sasho T. Safety and efficacy of intra-articular injection of platelet-rich plasma in patients with ankle osteoarthritis. Foot Ankle Int. 2017 Jun;38(6):596–604. doi: 10.1177/1071100717700377. [DOI] [PubMed] [Google Scholar]
  • 58.Cartron A.M., Shaikh G. Platelet-rich plasma: cure-all at what cost? Dermatol Surg. 2021 Feb 1;47(2):323. doi: 10.1097/DSS.0000000000002357. [DOI] [PubMed] [Google Scholar]
  • 59.Tuknayat A., Bhalla M., Thami G.P. Platelet‐rich plasma is a promising therapy for melasma. J Cosmet Dermatol. 2021 Aug;20(8):2431–2436. doi: 10.1111/jocd.14229. [DOI] [PubMed] [Google Scholar]
  • 60.Chen W.H., Lo W.C., Lee J.J., et al. Tissue‐engineered intervertebral disc and chondrogenesis using human nucleus pulposus regulated through TGF‐β1 in platelet‐rich plasma. J Cell Physiol. 2006 Dec;209(3):744–754. doi: 10.1002/jcp.20765. [DOI] [PubMed] [Google Scholar]
  • 61.Dhillon M.S., Patel S., Bansal T. Improvising PRP for use in osteoarthritis knee-upcoming trends and futuristic view. Journal of Clinical Orthopaedics and Trauma. 2019 Jan 1;10(1):32–35. doi: 10.1016/j.jcot.2018.10.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Cook C.S., Smith P.A. Clinical update: why PRP should be your first choice for injection therapy in treating osteoarthritis of the knee. Current reviews in musculoskeletal medicine. 2018 Dec;11:583–592. doi: 10.1007/s12178-018-9524-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Bhatia R., ChopRA G. Efficacy of platelet rich plasma via lumbar epidural route in chronic prolapsed intervertebral disc patients-a pilot study. J Clin Diagn Res: J Clin Diagn Res. 2016 Sep;10(9) doi: 10.7860/JCDR/2016/21863.8482. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Khatab S., van Buul G.M., Kops N., et al. Intra-articular injections of platelet-rich plasma releasate reduce pain and synovial inflammation in a mouse model of osteoarthritis. Am J Sports Med. 2018 Mar;46(4):977–986. doi: 10.1177/0363546517750635. [DOI] [PubMed] [Google Scholar]
  • 65.Xie X., Zhang C., Tuan R.S. Biology of platelet-rich plasma and its clinical application in cartilage repair. Arthritis Res Ther. 2014 Feb;16:1–5. doi: 10.1186/ar4493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Setiawan I.G., Suyasa I.K., Astawa P., Dusak I.W., Kawiyana I.K., Aryana I.G. Recombinant platelet derived growth factor-BB and hyaluronic acid effect in rat osteoarthritis models. J Orthop. 2019 May 1;16(3):230–233. doi: 10.1016/j.jor.2019.02.028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Xie X., Wang Y., Zhao C., et al. Comparative evaluation of MSCs from bone marrow and adipose tissue seeded in PRP-derived scaffold for cartilage regeneration. Biomaterials. 2012 Oct 1;33(29):7008–7018. doi: 10.1016/j.biomaterials.2012.06.058. [DOI] [PubMed] [Google Scholar]
  • 68.Zhao J., Huang H., Liang G., Zeng L.F., Yang W., Liu J. Effects and safety of the combination of platelet-rich plasma (PRP) and hyaluronic acid (HA) in the treatment of knee osteoarthritis: a systematic review and meta-analysis. BMC Muscoskel Disord. 2020 Dec;21:1–2. doi: 10.1186/s12891-020-03262-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Vannabouathong C., Bhandari M., Bedi A., et al. Nonoperative treatments for knee osteoarthritis: an evaluation of treatment characteristics and the intra-articular placebo effect: a systematic review. JBJS reviews. 2018 Jul 1;6(7) doi: 10.2106/JBJS.RVW.17.00167. [DOI] [PubMed] [Google Scholar]
  • 70.Raeissadat S.A., Babaee M., Rayegani S.M., et al. An overview of platelet products (PRP, PRGF, PRF, etc.) in the Iranian studies. Future science OA. 2017 Nov 1;3(4) doi: 10.4155/fsoa-2017-0045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Zhang Y., Morgan B.J., Smith R., et al. Platelet-rich plasma induces post-natal maturation of immature articular cartilage and correlates with LOXL1 activation. Sci Rep. 2017 Jun 16;7(1):3699. doi: 10.1038/s41598-017-02297-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Sakata R., McNary S.M., Miyatake K., et al. Stimulation of the superficial zone protein and lubrication in the articular cartilage by human platelet-rich plasma. Am J Sports Med. 2015 Jun;43(6):1467–1473. doi: 10.1177/0363546515575023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Sakata R., Reddi A.H. Platelet-rich plasma modulates actions on articular cartilage lubrication and regeneration. Tissue Eng B Rev. 2016 Oct 1;22(5):408–419. doi: 10.1089/ten.TEB.2015.0534. [DOI] [PubMed] [Google Scholar]
  • 74.Anitua E., Sánchez M., Nurden A.T., et al. Platelet-released growth factors enhance the secretion of hyaluronic acid and induce hepatocyte growth factor production by synovial fibroblasts from arthritic patients. Rheumatology. 2007 Dec 1;46(12):1769–1772. doi: 10.1093/rheumatology/kem234. [DOI] [PubMed] [Google Scholar]
  • 75.Di Martino A., Boffa A., Andriolo L., et al. Leukocyte-rich versus leukocyte-poor platelet-rich plasma for the treatment of knee osteoarthritis: a double-blind randomized trial. Am J Sports Med. 2022 Mar;50(3):609–617. doi: 10.1177/03635465211064303. [DOI] [PubMed] [Google Scholar]
  • 76.Kim J.H., Park Y.B., Ha C.W., Roh Y.J., Park J.G. Adverse reactions and clinical outcomes for leukocyte-poor versus leukocyte-rich platelet-rich plasma in knee osteoarthritis: a systematic review and meta-analysis. Orthopaedic Journal of Sports Medicine. 2021 Jun 29;9(6) doi: 10.1177/23259671211011948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Braun H.J., Kim H.J., Chu C.R., Dragoo J.L. The effect of platelet-rich plasma formulations and blood products on human synoviocytes: implications for intra-articular injury and therapy. Am J Sports Med. 2014 May;42(5):1204–1210. doi: 10.1177/0363546514525593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.McCarrel T.M., Minas T., Fortier L.A. Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy. JBJS. 2012 Oct 3;94(19) doi: 10.2106/JBJS.L.00019. [DOI] [PubMed] [Google Scholar]
  • 79.Lana J.F., Macedo A., Ingrao I.L., Huber S.C., Santos G.S., Santana M.H. Leukocyte-rich PRP for knee osteoarthritis: current concepts. Journal of clinical orthopaedics and trauma. 2019 Oct 1;10:S179–S182. doi: 10.1016/j.jcot.2019.01.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Ehrenfest D.M., Rasmusson L., Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte-and platelet-rich fibrin (L-PRF) Trends Biotechnol. 2009 Mar 1;27(3):158–167. doi: 10.1016/j.tibtech.2008.11.009. [DOI] [PubMed] [Google Scholar]
  • 81.Abbas A., Du J.T., Dhotar H.S. The effect of leukocyte concentration on platelet-rich plasma injections for knee osteoarthritis: a network meta-analysis. JBJS. 2022 Mar 16;104(6):559–570. doi: 10.2106/JBJS.20.02258. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Multimedia component 1
mmc1.docx (356.3KB, docx)
Multimedia component 2
mmc2.docx (45.5KB, docx)

Articles from Journal of Clinical Orthopaedics and Trauma are provided here courtesy of Elsevier

RESOURCES